Veracyte's (VCYT) progress with the three long-term growth drivers exhibits robust growth potential for the upcoming quarters. The record volume growth of the Decipher Prostrate test instills optimism, supported by the distinct recognition from the NCCN (National Comprehensive Cancer Network). The Afirma GRID offering can help the company extend its reach into the endocrinology market. Meanwhile, declining biopharma revenues and macroeconomic issues are worries for Veracyte. In the past year, this Zacks Ran ...

A month has gone by since the last earnings report for Veracyte (VCYT) . Shares have added about 9.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Veracyte's Q2 Earnings Top Estimates,'24 Sales View Up Ver ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed alo ...

After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Have you been paying attention to shares of Veracyte (VCYT) ? Shares have been on the move with the stock up 27.4% over the past month. The stock hit a new 52-week high of $32.86 in the previous session. Veracyte has gained 18.3% since the start of the year compared to the 8.2% move for the Zacks Medical sector and the 6.2% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earning ...

Veracyte (VCYT) delivered second-quarter 2024 adjusted diluted earnings of 30 cents per share, up a stupendous 150% from the year-ago period's level. The reported figure beat the Zacks Consensus Estimate of a loss of 3 cents per share. Revenues Revenues increased 26.7% year over year to $114.4 million, which outpaced the Zacks Consensus Estimate by 14%. Segmental Details Testing revenues totaled $107 million in the reported quarter, up 31% year over year. This rise was mainly due to increased Decipher and A ...

On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million. Testing revenue was $107.0 million, an increase of 31%, driven by the strong performance of our Decipher Prostate and Afirma tests. Total test volume grew to 39,023, an increase of 23% compared to the second quarter of 2023. During the quarter, the company achieved a record Decipher Prostate test volume of close to 19,900 tests, driven by recently updated NCCN pros ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 20-5455398 (State or other ...

Veracyte, Inc. (NASDAQ:VCYT) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Shayla Gorman – Senior Director, Investor Relations Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Conference Call Participants Mason Carrico – Stephens, Inc. Yuko Oku – Morgan Stanley Maggie Boeye – William Blair Joseph Conway – Needham & Company Prashant Kota – Goldman Sachs Thomas DeBourcy – Nephron Research Operator Good day and thank you for standing by. Welcom ...